|
TOP NEWS
Panel Rejects BMS Investor's Bid To 'Camouflage A Wolf'
By George Woolston
A New Jersey state appeals court said an investor's amended complaint over Bristol-Myers Squibb Co.'s $74 billion acquisition of Celgene Corp. was a wolf camouflaged in sheep's clothing, finding that the investor's claims of disclosure requirement shortfalls sounded more in fraud than negligence and failed to satisfy the heightened pleading standard required.
Opinion attached |
Read full article »
| Save to favorites »
ENFORCEMENT
LITIGATION
THIRD CIRCUIT
EXPERT ANALYSIS
LEGAL INDUSTRY
|